Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Maia Biotechnology Inc

MAIA ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.40

▲ +4.48%

Market Cap $85.16M · Vol 23.94K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$85.16M

Micro Cap

Div Yield

N/A

EPS Growth

+25.71%

YoY

RSI (14)

63.64

Momentum

Beta

0.29

vs Market

52W High

$3.16

55.70% below

52W Low

$0.87

60.92% above

Volume

23.94K

Avg 45.01K

P/B

24.87

Price-to-book

ROE

N/A

Return on equity

Free Float

85.62%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Maia Biotechnology Inc (MAIA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MAIA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.41%

-2.78%

+2.94%

-27.08%

YTD

-8.50%

-10.26%

-30.69%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-22,396,170.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-225.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	24.87
P/FCF	N/A
EPS Growth	+25.71%
Outstanding Shares	60.83M

Technical Indicators

50-Day SMA	$1.36
200-Day SMA	$1.46
RSI (14)	63.64
Beta	0.29
52-Week High	$3.16
52-Week Low	$0.87

Volume Today	23.94K
Avg Daily Volume (30D)	45.01K
Relative Volume	0.53x
Volatility (10D)	41.57
Volatility (30D)	48.37
Free Float	85.62%

Analyst Consensus

BUY

Current Price $1.40

Mean Target $12.14

52W Low$0.87 52W High$3.16

Current

Target

$0.87 $3.16

Current Analyst target

+766.79% upside potential · 1 analysts

Identifiers

ExchangeNYSE American

FIGIBBG0113Q7J97

ISINUS5526411021

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.